Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hecolin in Chronic Hepatitis B Patients
NCT02964910Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of HEV 239 in hepatitis E (HEV) (2 arms), sponsored by Xiamen Innovax Biotech Co., Ltd. Primary endpoints: Number of Participants Whose Anti-HEV Antibody Seroconverted at Month 7 and Geometric Mean Concentrations of Anti-HEV Antibody at Month 7. Started Aug 2016; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT02964910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964910.